Publications
Publications as a Result of Core Usage
Sergina N, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM. Resistance to HER family tyrosine kinase inhibitors by the kinase inactive HER3. Nature, (in press)
Marx C, Berger C, Xu F, Amend C, Scott GK, Hann B, Park JW, Benz CC. Validated High-Throughput Screening of Drug-Like Small Molecules for Inhibitors of ErbB2 Transcription. Assay Drug Dev Technol. 2006 Jun;4(3):273-84.
Kirpotin DB, Drummond DC, Hong K, Shao Y, Shalaby R, Nielsen UB, Marks JD, Benz CC, and Park JW. Antibody targeting of long circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006, 66(13)6732-40.
Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 2006 Mar 15;66(6):3271-7.
Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB, Park JW. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 2005 Dec 15;65(24):11631-8.
Li KL, Wilmes LJ, Henry RG, Pallavicini MG, Park JW, Hu-Lowe DD, McShane TM, Shalinsky DR, Fu YJ, Brasch RC, Hylton NM. Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI. J Magn Reson Imaging. 2005 Oct;22(4):511-9.
Drummond DC, Marx C, Guo Z, Scott G, Noble C, Wang D, Pallavicini M, Park JW, Kirpotin DB, and Benz CC. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes. Clin Cancer Res. 2005, 11(9):3392-401
Moasser MM, Li KL, Wilmes L, Wang D, Hann B, Hylton N. Transiently improved tumor vascular perfusion and permeability following HER family tyrosine kinase inhibitor therapy. (in submission).
Liu, B, Conrad, F, Roth, A., Drummond, DC Simko, J & Marks, JD, Recombinant Full-length Human IgG1s Targeting Hormone Refractory Prostate Cancer (in submission).
